sign in sign up
<<
Home , Muscle relaxant

NEWS Once-daily relaxant in SA

Myprocam ( with spine-related disorders and other 8. What are the classes of muscle a protective coating, and a polymer extended release [ER] sports injuries are excellent candidates relaxants? membrane that controls the rate of hydrochloride) is the most widely for Myprocam. Skeletal muscle relaxants (SMRs) are release. prescribed skeletal muscle a group of structurally unrelated , The formulation of the drug relaxant in the US, is now available 4. What are the common as shown in Figure 1. These are divided ensures early systemic exposure in SA. Myprocam’s safety and efficacy indications for which Myprocam into two categories: to cyclobenzaprine, with a plasma has been shown in more than 20 clinical is used, and what are the common • Antispasticity agents: Used to concentration at four hours that trials. It was recently launched by causes of these ailments? treat muscle caused by is similar to that observed with Adcock Ingram nationally, making SA Low back , , sports traumatic neurologic injury, multiple cyclobenzaprine IR. the second country (only to the US) to injuries, muscle sprains and strains. sclerosis, and other conditions. However, in contrast to the bring the product to market. Common causes of these conditions •  agents: Used fluctuating peaks and troughs in Myprocam, indicated for the relief of include sports injuries, car accidents, to treat muscular pain or plasma cyclobenzaprine concentration muscle spasm associated with acute work-related injuries, and everyday associated with acute, nonspecific after administration of the IR and painful musculoskeletal conditions, activities, which account for acute musculoskeletal conditions. formulation three times daily, plasma was previously only available in other orthopedic injuries. Cyclobenzaprine is the most cyclobenzaprine concentration with the countries in immediate release (IR) commonly prescribed skeletal ER formulation is sustained over 5mg and 10mg formulations with 5. Patients often take a range of muscle relaxant in the US and has 24 hours following the administration three-times-a-day dosing. It is now drugs for pain. What other drugs been shown to relieve muscle spasm of a single dose. available in 15mg and 30mg versions, can Myprocam be taken with? without interfering with muscle as ER once-daily formulations. It Non-steroidal anti-inflammatory drugs function. It is structurally similar to is packaged in 30s, but could be and drugs. tricyclic and exhibits prescribed in less quantity if preferred. activity. Dr Arnold Weil, who specialises 6. What drug interactions should The ER formula was developed in non-surgical orthopaedics and has healthcare practitioners look to maximise the clinical benefit of been involved in many of the trials out for? cyclobenzaprine and to increase on cyclobenzaprine, was one of the Avoid Myprocam with use. tolerability. Cyclobenzaprine ER is international speakers at the launch the only once-daily skeletal muscle event. He recently shared the following 7. Are there any elements in a relaxant available and makes use of the in an interview with Medical Chronicle patient’s history that should be red Diffucaps® drug delivery technology. Editor, Claire Smith. flags for prescribing Myprocam? The Diffucaps beads contained in Use with caution in elderly patients, each capsule consist of an inert (sugar) 1. What are the benefits of the patients on beta blockers and patients core in the centre surrounded by a extended-release formulation? with cardiac disease. layer of active drug (cyclobenzaprine), DR ARNOLD WEIL The ability for the patient to take one pill a day and get the full effect for 24 hours. This helps with patient Figure compliance and efficacy of the 1 SKELETAL MUSCLE RELAXANT , since the patient doesn’t have to remember to take it three or four times a day to get the full effect. SMRs 2. Cyclobenzaprine is one of the most studied molecules in the Antispasticity world. What were some of the Antispasmodic (muscle spasm) (spasticity affecting striking findings of the extended- function) release version trials that you were involved in? It showed fewer adverse events than the TID dosing of the short-acting Nonbenzodiapines cyclobenzaprine, greater efficacy than placebo and was well tolerated by patients in the trials. In clinical practice, this holds true. Patients have few side effects and the Cylobenzaprine incidence of sedation is much less with the extended release Myprocam than the immediate release cyclobenzaprine. As a result, patients get much better relief of muscle spasm.

3. What patients are the best candidates for this product? Patients with acute muscle spasm who require treatment in addition to physical therapy to help with musculoskeletal pain associated with muscle spasm. Almost every patient with acute back and neck pain has a component of muscle spasm. Patients

2 MEDICAL CHRONICLE NOVEMBER 2014